Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

543 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19.
Boras B, Jones RM, Anson BJ, Arenson D, Aschenbrenner L, Bakowski MA, Beutler N, Binder J, Chen E, Eng H, Hammond H, Hammond J, Haupt RE, Hoffman R, Kadar EP, Kania R, Kimoto E, Kirkpatrick MG, Lanyon L, Lendy EK, Lillis JR, Logue J, Luthra SA, Ma C, Mason SW, McGrath ME, Noell S, Obach RS, O' Brien MN, O'Connor R, Ogilvie K, Owen D, Pettersson M, Reese MR, Rogers TF, Rosales R, Rossulek MI, Sathish JG, Shirai N, Steppan C, Ticehurst M, Updyke LW, Weston S, Zhu Y, White KM, García-Sastre A, Wang J, Chatterjee AK, Mesecar AD, Frieman MB, Anderson AS, Allerton C. Boras B, et al. Among authors: binder j. Nat Commun. 2021 Oct 18;12(1):6055. doi: 10.1038/s41467-021-26239-2. Nat Commun. 2021. PMID: 34663813 Free PMC article.
Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19.
Boras B, Jones RM, Anson BJ, Arenson D, Aschenbrenner L, Bakowski MA, Beutler N, Binder J, Chen E, Eng H, Hammond H, Hammond J, Haupt RE, Hoffman R, Kadar EP, Kania R, Kimoto E, Kirkpatrick MG, Lanyon L, Lendy EK, Lillis JR, Logue J, Luthra SA, Ma C, Mason SW, McGrath ME, Noell S, Obach RS, O'Brien MN, O'Connor R, Ogilvie K, Owen D, Pettersson M, Reese MR, Rogers TF, Rossulek MI, Sathish JG, Shirai N, Steppan C, Ticehurst M, Updyke LW, Weston S, Zhu Y, Wang J, Chatterjee AK, Mesecar AD, Frieman MB, Anderson AS, Allerton C. Boras B, et al. Among authors: binder j. bioRxiv [Preprint]. 2021 Feb 12:2020.09.12.293498. doi: 10.1101/2020.09.12.293498. bioRxiv. 2021. PMID: 32935104 Free PMC article. Updated. Preprint.
A comparative analysis of SARS-CoV-2 antivirals characterizes 3CLpro inhibitor PF-00835231 as a potential new treatment for COVID-19.
de Vries M, Mohamed AS, Prescott RA, Valero-Jimenez AM, Desvignes L, O'Connor R, Steppan C, Devlin JC, Ivanova E, Herrera A, Schinlever A, Loose P, Ruggles K, Koralov SB, Anderson AS, Binder J, Dittmann M. de Vries M, et al. Among authors: binder j. J Virol. 2021 Mar 10;95(7):e01819-20. doi: 10.1128/JVI.01819-20. Epub 2021 Feb 23. J Virol. 2021. PMID: 33622961 Free PMC article.
A comparative analysis of SARS-CoV-2 antivirals in human airway models characterizes 3CLpro inhibitor PF-00835231 as a potential new treatment for COVID-19.
de Vries M, Mohamed AS, Prescott RA, Valero-Jimenez AM, Desvignes L, O'Connor R, Steppan C, Devlin JC, Ivanova E, Herrera A, Schinlever A, Loose P, Ruggles K, Koralov SB, Anderson AS, Binder J, Dittmann M. de Vries M, et al. Among authors: binder j. bioRxiv [Preprint]. 2021 Feb 19:2020.08.28.272880. doi: 10.1101/2020.08.28.272880. bioRxiv. 2021. PMID: 32869028 Free PMC article. Updated. Preprint.
Oncolytic Vaccinia Virus Gene Modification and Cytokine Expression Effects on Tumor Infection, Immune Response, and Killing.
Inoue T, Byrne T, Inoue M, Tait ME, Wall P, Wang A, Dermyer MR, Laklai H, Binder JJ, Lees C, Hollingsworth R, Maruri-Avidal L, Kirn DH, McDonald DM. Inoue T, et al. Among authors: binder jj. Mol Cancer Ther. 2021 Aug;20(8):1481-1494. doi: 10.1158/1535-7163.MCT-20-0863. Epub 2021 May 27. Mol Cancer Ther. 2021. PMID: 34045231 Free PMC article.
Characterization of Recombinant Chimpanzee Adenovirus C68 Low and High-Density Particles: Impact on Determination of Viral Particle Titer.
Mullins EK, Powers TW, Zobel J, Clawson KM, Barnes LF, Draper BE, Zou Q, Binder JJ, Dai S, Zhang K, Friese O, Runnels HA, Jarrold MF, Thompson LC. Mullins EK, et al. Among authors: binder jj. Front Bioeng Biotechnol. 2021 Nov 4;9:753480. doi: 10.3389/fbioe.2021.753480. eCollection 2021. Front Bioeng Biotechnol. 2021. PMID: 34805110 Free PMC article.
Preclinical development of a vaccine-based immunotherapy regimen (VBIR) that induces potent and durable T cell responses to tumor-associated self-antigens.
Cho H, Binder J, Weeratna R, Dermyer M, Dai S, Boccia A, Li W, Li S, Jooss K, Merson J, Hollingsworth RE. Cho H, et al. Among authors: binder j. Cancer Immunol Immunother. 2023 Feb;72(2):287-300. doi: 10.1007/s00262-022-03245-x. Epub 2022 Jul 13. Cancer Immunol Immunother. 2023. PMID: 35829790 Free PMC article.
543 results